Literature DB >> 17167526

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia.

P Ghia, K Stamatopoulos, C Belessi, C Moreno, S Stilgenbauer, F Stevenson, F Davi, R Rosenquist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17167526     DOI： 10.1038/sj.leu.2404457

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  65 in total

1.  microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.

Authors:  Stefan Deneberg; Meena Kanduri; Dina Ali; Sofia Bengtzen; Mohsen Karimi; Ying Qu; Eva Kimby; Larry Mansouri; Richard Rosenquist; Andreas Lennartsson; Sören Lehmann
Journal:  Epigenetics       Date:  2014-03-31       Impact factor: 4.528

2.  Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients.

Authors:  Tycho Baumann; Riccardo Moia; Gianluca Gaidano; Julio Delgado; Adalgisa Condoluci; Neus Villamor; Anil Babu Payedimarri; Dolors Costa; Andrea Patriarca; Carlos Jiménez-Vicente; Davide Rossi; Emili Montserrat
Journal:  Leukemia       Date:  2021-02-04       Impact factor: 11.528

3.  Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.

Authors:  Emanuela M Ghia; Sonia Jain; George F Widhopf; Laura Z Rassenti; Michael J Keating; William G Wierda; John G Gribben; Jennifer R Brown; Kanti R Rai; John C Byrd; Neil E Kay; Andrew W Greaves; Thomas J Kipps
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

4.  B-cell clones as early markers for chronic lymphocytic leukemia.

Authors:  Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

5.  The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells.

Authors:  Laia Rosich; Ifigènia Saborit-Villarroya; Mónica López-Guerra; Sílvia Xargay-Torrent; Arnau Montraveta; Marta Aymerich; Neus Villamor; Elias Campo; Patricia Pérez-Galán; Gaël Roué; Dolors Colomer
Journal:  Haematologica       Date:  2013-07-12       Impact factor: 9.941

6.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

7.  The European LeukemiaNet: achievements and perspectives.

Authors:  Rüdiger Hehlmann; David Grimwade; Bengt Simonsson; Jane Apperley; Michele Baccarani; Tiziano Barbui; Giovanni Barosi; Renato Bassan; Marie C Béné; Ute Berger; Thomas Büchner; Alan Burnett; Nicolas C P Cross; Theo J M de Witte; Hartmut Döhner; Hervé Dombret; Hermann Einsele; Georg Engelich; Robin Foà; Christa Fonatsch; Nicola Gökbuget; Elaine Gluckman; Alois Gratwohl; Francois Guilhot; Claudia Haferlach; Thorsten Haferlach; Michael Hallek; Jörg Hasford; Andreas Hochhaus; Dieter Hoelzer; Jean-Jaques Kiladjian; Boris Labar; Per Ljungman; Ulrich Mansmann; Dietger Niederwieser; Gert Ossenkoppele; José M Ribera; Harald Rieder; Hubert Serve; Petra Schrotz-King; Miguel A Sanz; Susanne Saussele
Journal:  Haematologica       Date:  2010-11-03       Impact factor: 9.941

Review 8.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

9.  Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling.

Authors:  M Hahn; J-P Bürckert; C A Luttenberger; S Klebow; M Hess; M Al-Maarri; M Vogt; S Reißig; M Hallek; A Wienecke-Baldacchino; T Buch; C P Muller; C P Pallasch; F T Wunderlich; A Waisman; N Hövelmeyer
Journal:  Leukemia       Date:  2017-06-01       Impact factor: 11.528

10.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.